Stimulus package

Stimulus package, Published online: 06 March 2018; doi:10.1038/nm.4515

Therapies for Alzheimer's disease and other neurodegenerative diseases are desperately needed. Yet, a string of disappointments in the neurodegenerative therapy space has meant that several companies over the years have ended their investment in the field. Some companies have diversified their research and development (R&D) models to hedge their bets. Maintaining this diversity to bring down the silos between big pharma and smaller research teams may be necessary to jumpstart and sustain progress in combatting neurodegenerative conditions.

中文翻译：

---

刺激套餐

刺激套餐

刺激方案，在线发布：2018年3月6日; doi：10.1038 / nm.4515

迫切需要用于阿尔茨海默氏病和其他神经退行性疾病的疗法。然而，神经退行性治疗领域的一系列令人失望的事情表明，多年来有几家公司终止了对该领域的投资。一些公司已经通过多样化的研发（R＆D）模型来对冲自己的赌注。保持这种多样性以减少大型制药公司和较小的研究团队之间的孤岛，可能对于快速启动并维持对抗神经退行性疾病的进展可能是必要的。